The Bcl-2-inhibitor venetoclax and the c-IAP1/c-IAP2 inhibitor BV6 can enhance TMZ toxicity at early times after TMZ treatment and, most importantly, also target senescent glioblastoma cells at later times. The gene discussed is BIRC2; the disease is glioblastoma.